Literature DB >> 29142048

Accurate PCR Detection of Influenza A/B and Respiratory Syncytial Viruses by Use of Cepheid Xpert Flu+RSV Xpress Assay in Point-of-Care Settings: Comparison to Prodesse ProFlu.

Daniel M Cohen1, Jennifer Kline2, Larissa S May3, Glenn Eric Harnett4, Jane Gibson5, Stephen Y Liang6, Zubaid Rafique7, Carina A Rodriguez8, Kevin M McGann9, Charlotte A Gaydos10, Donna Mayne11, David Phillips12, Jason Cohen13.   

Abstract

The Xpert Flu+RSV Xpress Assay is a fast, automated in vitro diagnostic test for qualitative detection and differentiation of influenza A and B viruses and respiratory syncytial virus (RSV) performed on the Cepheid GeneXpert Xpress System. The objective of this study was to establish performance characteristics of the Xpert Flu+RSV Xpress Assay compared to those of the Prodesse ProFlu+ real-time reverse transcription-PCR (RT-PCR) assay (ProFlu+) for the detection of influenza A and B viruses as well as RSV in a Clinical Laboratory Improvement Amendments (CLIA)-waived (CW) setting. Overall, the assay, using fresh and frozen nasopharyngeal (NP) swabs, demonstrated high concordance with results of the ProFlu+ assay in the combined CW and non-CW settings with positive percent agreements (PPA) (100%, 100%, and 97.1%) and negative percent agreements (NPA) (95.2%, 99.5%, and 99.6%) for influenza A and B viruses and RSV, respectively. In conclusion, this multicenter study using the Cepheid Xpert Flu+RSV Xpress Assay demonstrated high sensitivities and specificities for influenza A and B viruses and RSV in ∼60 min for use at the point-of-care in the CW setting.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  CLIA-waived; DNA polymerase; influenza; respiratory syncytial virus

Mesh:

Substances:

Year:  2018        PMID: 29142048      PMCID: PMC5786727          DOI: 10.1128/JCM.01237-17

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  18 in total

Review 1.  Influenza.

Authors:  Angelena M Labella; Susan E Merel
Journal:  Med Clin North Am       Date:  2013-07       Impact factor: 5.456

2.  Evaluation of the Alere i Influenza A&B assay for rapid identification of influenza A and influenza B viruses.

Authors:  Flavia Cecilia Chiarella; Esther Culebras; Manuel Enrique Fuentes-Ferrer; Juan José Picazo
Journal:  J Med Microbiol       Date:  2016-03-11       Impact factor: 2.472

3.  Prospective evaluation of the Alere i Influenza A&B nucleic acid amplification versus Xpert Flu/RSV.

Authors:  J C Nguyen Van; F Caméléna; M Dahoun; B Pilmis; A Mizrahi; J Lourtet; S Behillil; V Enouf; A Le Monnier
Journal:  Diagn Microbiol Infect Dis       Date:  2015-12-01       Impact factor: 2.803

4.  Performance of the molecular Alere I influenza A&B test compared to that of the xpert flu A/B assay.

Authors:  Kimberle C Chapin; Estefany J Flores-Cortez
Journal:  J Clin Microbiol       Date:  2014-12-10       Impact factor: 5.948

5.  Utility of early influenza diagnosis through point-of-care testing in children presenting to an emergency department.

Authors:  Jean Li-Kim-Moy; Fereshteh Dastouri; Harunor Rashid; Gulam Khandaker; Alison Kesson; Mary McCaskill; Nicholas Wood; Cheryl Jones; Yvonne Zurynski; Kristine Macartney; Elizabeth J Elliott; Robert Booy
Journal:  J Paediatr Child Health       Date:  2016-04       Impact factor: 1.954

6.  Multicenter clinical evaluation of the novel Alere™ i Influenza A&B isothermal nucleic acid amplification test.

Authors:  Jeremiah Bell; Aleta Bonner; Daniel M Cohen; Robert Birkhahn; Ram Yogev; Wayne Triner; Jason Cohen; Elizabeth Palavecino; Rangaraj Selvarangan
Journal:  J Clin Virol       Date:  2014-06-07       Impact factor: 3.168

7.  Economic Impact of a New Rapid PCR Assay for Detecting Influenza Virus in an Emergency Department and Hospitalized Patients.

Authors:  Marcelo Soto; Laura Sampietro-Colom; Anna Vilella; Efraín Pantoja; María Asenjo; Ruth Arjona; Juan Carlos Hurtado; Antoni Trilla; Míriam José Alvarez-Martínez; Aurea Mira; Jordi Vila; María Angeles Marcos
Journal:  PLoS One       Date:  2016-01-20       Impact factor: 3.240

8.  Analytical performance of the Alere™ i Influenza A&B assay for the rapid detection of influenza viruses.

Authors:  Cristina Riazzo; Mercedes Pérez-Ruiz; Sara Sanbonmatsu-Gámez; Irene Pedrosa-Corral; José Gutiérrez-Fernández; José-María Navarro-Marí
Journal:  Enferm Infecc Microbiol Clin       Date:  2015-11-25       Impact factor: 1.731

9.  Predictors of severe H1N1 infection in children presenting within Pediatric Emergency Research Networks (PERN): retrospective case-control study.

Authors:  Stuart R Dalziel; John Md Thompson; Charles G Macias; Ricardo M Fernandes; David W Johnson; Yehezkel Waisman; Nicholas Cheng; Jason Acworth; James M Chamberlain; Martin H Osmond; Amy Plint; Paolo Valerio; Karen Jl Black; Eleanor Fitzpatrick; Amanda S Newton; Nathan Kuppermann; Terry P Klassen
Journal:  BMJ       Date:  2013-08-12

Review 10.  Point-of-care testing for respiratory viruses in adults: The current landscape and future potential.

Authors:  Nathan J Brendish; Hannah F Schiff; Tristan W Clark
Journal:  J Infect       Date:  2015-07-26       Impact factor: 6.072

View more
  18 in total

1.  Paying for Point-of-Care Nucleic Acid Amplification Tests: a Micro-Comic Strip.

Authors:  Alexander J McAdam
Journal:  J Clin Microbiol       Date:  2018-05-25       Impact factor: 5.948

2.  Profile of the Alere i Influenza A & B assay: a pioneering molecular point-of-care test.

Authors:  Hongmei Wang; Jikui Deng; Yi-Wei Tang
Journal:  Expert Rev Mol Diagn       Date:  2018-04-24       Impact factor: 5.225

3.  Impact of Rapid Molecular Detection of Respiratory Viruses on Clinical Outcomes and Patient Management.

Authors:  Jane Kuypers
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

4.  Parallel Validation of Three Molecular Devices for Simultaneous Detection and Identification of Influenza A and B and Respiratory Syncytial Viruses.

Authors:  Lifen Ling; Samuel E Kaplan; Juan C Lopez; Jeffrey Stiles; Xuedong Lu; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2018-02-22       Impact factor: 5.948

5.  Comparison of Six Sample-to-Answer Influenza A/B and Respiratory Syncytial Virus Nucleic Acid Amplification Assays Using Respiratory Specimens from Children.

Authors:  Dithi Banerjee; Neena Kanwar; Ferdaus Hassan; Cynthia Essmyer; Rangaraj Selvarangan
Journal:  J Clin Microbiol       Date:  2018-10-25       Impact factor: 5.948

6.  Diagnostic accuracy of a rapid RT-PCR assay for point-of-care detection of influenza A/B virus at emergency department admission: A prospective evaluation during the 2017/2018 influenza season.

Authors:  Maxime Maignan; Damien Viglino; Maud Hablot; Nicolas Termoz Masson; Anne Lebeugle; Roselyne Collomb Muret; Prudence Mabiala Makele; Valérie Guglielmetti; Patrice Morand; Julien Lupo; Virginie Forget; Caroline Landelle; Sylvie Larrat
Journal:  PLoS One       Date:  2019-05-07       Impact factor: 3.240

Review 7.  Cost-Effective Respiratory Virus Testing.

Authors:  B A Pinsky; R T Hayden
Journal:  J Clin Microbiol       Date:  2019-08-26       Impact factor: 5.948

8.  RNA respiratory viral infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.

Authors:  Oriol Manuel; Michele Estabrook
Journal:  Clin Transplant       Date:  2019-03-22       Impact factor: 2.863

9.  Clinical outcomes of adults hospitalized for laboratory confirmed respiratory syncytial virus or influenza virus infection.

Authors:  Magdalena Chorazka; Domenica Flury; Kathrin Herzog; Werner C Albrich; Danielle Vuichard-Gysin
Journal:  PLoS One       Date:  2021-07-22       Impact factor: 3.240

10.  Point-of-Care Screening for a Current Hepatitis C Virus Infection: Influence on Uptake of a Concomitant Offer of HIV Screening.

Authors:  Anna Maria Geretti; Harrison Austin; Giovanni Villa; Dan Hungerford; Colette Smith; Paula Davies; Jillian Williams; Apostolos Beloukas; Wojciech Sawicki; Mark Hopkins
Journal:  Sci Rep       Date:  2018-10-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.